Neurimmune Starts Treatment in Phase 2 Trial

(CONNECT) Neurimmune has dosed a first patient in a new trial of the drug Cliramitug, according to a statement from the Schlieren-based biopharmaceutical company. Cliramitug is used to treat transthyretin amyloidosis with cardiomyopathy (ATTR-CM), a rare and life-threatening heart disease.

In the follow-up study, the effect and safety of the drug will be tested. Only patients who had previously participated in a feasibility study for Cliramitug were recruited. Neurimmune is responsible for conducting the Phase 2 follow-up study under a license agreement with Alexion Pharmaceuticals of Boston, Massachusetts. Alexion itself, which as part of AstraZeneca specializes in rare diseases, is currently conducting a phase 3 study on the efficacy of the drug.

"The start of this Phase 2 follow-up study is an important step in our collaboration with Alexion, allowing us to expand our understanding of the long-term treatment effects of Cliramitug," Christoph Hock, Chief Medical Officer at Neurimmune, is quoted in the press release.

Neurimmune was spun off from the University of Zurich in 2006 and is based in the Bio-Technopark Schlieren-Zurich. ce/jh